Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FURESTEM-CD in Moderate to Severe Plaque-type Psoriasis
NCT02918123Phase 1Unknown
- Sponsor
- Kangstem Biotech
- Start
- Jan 2018
- Primary completion
- Dec 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of furestem-cd in plaque psoriasis, sponsored by Kangstem Biotech. Primary endpoints: Number of adverse events at 4 weeks, Safety lab tests at 4 weeks and 6 more. Status: unknown.
02
Drugs
furestem-cd
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02918123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918123.